Home > Publications database > Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer. > print

001     299826
005     20250323015713.0
024 7 _ |a 10.1002/1878-0261.13797
|2 doi
024 7 _ |a pmid:40084488
|2 pmid
024 7 _ |a 1574-7891
|2 ISSN
024 7 _ |a 1878-0261
|2 ISSN
024 7 _ |a altmetric:175218654
|2 altmetric
037 _ _ |a DKFZ-2025-00563
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Isebia, Khrystany T
|0 0000-0002-3006-5206
|b 0
245 _ _ |a Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.
260 _ _ |a Hoboken, NJ
|c 2025
|b John Wiley & Sons, Inc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1742292049_21169
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing system (mFast-SeqS), a quick, tumor-agnostic and affordable ctDNA assay that requires a small input of DNA, to generate a genome-wide aneuploidy (GWA) score in mCRPC patients, and correlated this to matched metastatic tumor biopsies. In this prospective multicenter study, GWA scores were evaluated from blood samples of 196 mCRPC patients prior to treatment (baseline) with taxanes (docetaxel and cabazitaxel) and androgen receptor signaling inhibitors (ARSI; abiraterone and enzalutamide), and from 74 mCRPC patients at an early timepoint during treatment (early timepoint; median 21 days). Z-scores per chromosome arm were tested for their association with tumor tissue genomic alterations. We found that a high tumor load in blood (GWAhigh) at baseline was associated with poor response to ARSI [HR: 2.63 (95% CI: 1.86-3.72) P < 0.001] but not to taxanes. Interestingly, GWAhigh score at the early timepoint was associated with poor response to both ARSIs [HR: 6.73 (95% CI: 2.60-17.42) P < 0.001] and taxanes [2.79 (95% CI: 1.34-5.78) P = 0.006]. A significant interaction in Cox proportional hazards analyses was seen when combining GWA status and type of treatment (at baseline P = 0.008; early timepoint P = 0.018). In summary, detection of ctDNA in blood by mFast-SeqS is cheap, fast and feasible, and could be used at different timepoints as a potential predictor for outcome to ARSI and taxane treatment in mCRPC.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a abiraterone
|2 Other
650 _ 7 |a cabazitaxel
|2 Other
650 _ 7 |a ctDNA
|2 Other
650 _ 7 |a docetaxel
|2 Other
650 _ 7 |a enzalutamide
|2 Other
650 _ 7 |a prostate cancer
|2 Other
700 1 _ |a de Jong, Anouk C
|0 0000-0002-7381-3171
|b 1
700 1 _ |a van Dessel, Lisanne F
|b 2
700 1 _ |a de Weerd, Vanja
|b 3
700 1 _ |a Beaufort, Corine
|b 4
700 1 _ |a Helmijr, Jean
|b 5
700 1 _ |a Nakauma-González, José Alberto
|0 0000-0002-9153-4280
|b 6
700 1 _ |a van Riet, Job
|0 P:(DE-He78)6efdda844232d585b4472cecaed85382
|b 7
|u dkfz
700 1 _ |a Hamberg, Paul
|b 8
700 1 _ |a Vis, Daniel
|b 9
700 1 _ |a van der Heijden, Michiel S
|b 10
700 1 _ |a Beije, Nick
|b 11
700 1 _ |a Lolkema, Martijn P
|b 12
700 1 _ |a Deger, Teoman
|0 0000-0002-3055-3066
|b 13
700 1 _ |a Wilting, Saskia M
|b 14
700 1 _ |a de Wit, Ronald
|b 15
700 1 _ |a Jansen, Maurice P H M
|0 0000-0003-1258-9804
|b 16
700 1 _ |a Martens, John W M
|0 0000-0002-3428-3366
|b 17
773 _ _ |a 10.1002/1878-0261.13797
|g p. 1878-0261.13797
|0 PERI:(DE-600)2322586-5
|p nn
|t Molecular oncology
|v nn
|y 2025
|x 1574-7891
909 C O |o oai:inrepo02.dkfz.de:299826
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)6efdda844232d585b4472cecaed85382
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:04:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2024-08-08T17:04:26Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-He78)B450-20160331
|k B450
|l Künstl. Intelligenz in der Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B450-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21